Mattia Garancini

Dr. Mattia Garancini


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Vanna DentiVanna Denti
Vanna Denti
AGAngela Greco
Angela Greco
AAAntonio Maria Alviano
Antonio Maria Alviano
GCGiulia Capitoli
Giulia Capitoli
NMNicole Monza
Nicole Monza
FPFabio Pagni
Fabio Pagni
Follicular-patterned thyroid neoplasms comprise a diverse group of lesions that pose significant challenges in terms of differential diagnosis based solely on morphologic and genetic features. Thus, the identification of easily testable biomarkers complementing microscopic and genetic analyses is a highly anticipated advancement that could improve diagnostic accuracy, particularly for noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTPs). These tumors exhibit considerable morphological and molecular heterogeneity, which may complicate their distinction from structurally similar neoplasms, especially when genetic analyses reveal shared genomic alterations (e.g., RAS mutations). Here, we integrated next-generation sequencing (NGS) with matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to perform a proteogenomic analysis on 85 NIFTPs (n = 30 RAS-mutant [RAS-mut] and n = 55 RAS-wild type [RAS-wt]), with the aim to detect putative biomarkers of RAS-mut lesions. Through this combined approach, we identified four proteins that were significantly underexpressed in RAS-mut as compared to RAS-wt NIFTPs. These proteins could serve as readily accessible markers in morphologically borderline cases showing RAS mutations. Additionally, our findings may provide insights into the distinct pathogenic pathways through which RAS-mut and RAS-wt NIFTPs arise, highlighting the pivotal role of constitutive RAS–mitogen-activated protein kinase (MAPK) pathway activation in the development and progression of RAS-mut tumors.

15 July 2024 in Livers
Verified
Journal Article
Open access
PDF file
FFFederica Ferraina
Federica Ferraina
AFAlessandro Fogliati
Alessandro Fogliati
MSMauro Alessandro Scotti
Mauro Alessandro Scotti
Fabrizio RomanoFabrizio Romano
Fabrizio Romano
MGMattia Garancini
Mattia Garancini
CCCristina Ciulli
Cristina Ciulli
Segmental or lobar liver atrophy is a common but not well-understood clinical condition. Hepatic atrophy can be classified into hepatic atrophy secondary to other pathologies and primary segmental hepatic atrophy, which is a benign intrahepatic lesion (pseudotumor) not associated with any other pathology. The pathophysiological mechanisms underlying atrophy can be divided into three main situations: obstruction of biliary outflow, obstruction of the systemic venous outflow, and obstruction of incoming portal venous flow. For what may concern secondary hepatic atrophy, there are many pathologies that could underlie this condition, ranging from benign to intrahepatic malignancies, with particular reference to particularly hepatocellular carcinoma and biliary duct carcinoma. An accurate and prompt differential diagnosis between the various forms and causes of atrophy is important for early identification and adequate treatment of underlying pathologies. A comprehensive review of the literature on the etiology and the radiological and histological characteristics of different types of hepatic atrophy is currently unavailable. Therefore, the aim of this review is to summarize the primary and secondary causes of segmental or lobar liver atrophy (excluding forms involving the entire liver parenchyma) and to provide practical tools for clinical and radiological differential diagnosis.

10 September 2026 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CCCristina Ciulli
Cristina Ciulli
ESEmanuele Scarpa
Emanuele Scarpa
PCPasquale Chiacchio
Pasquale Chiacchio
AFAlessandro Fogliati
Alessandro Fogliati
MSMauro Alessandro Scotti
Mauro Alessandro Scotti
FRFabrizio Romano
Fabrizio Romano